Polish court rejects call to remove crucifix from parliament

WARSAW (Reuters) – A Polish court has rejected a motion calling for the removal of a crucifix from parliament’s debating chamber in a case pitting Poland’s traditional Catholicism against a younger generation who think the church is too strong. Warsaw’s district court late on Monday argued that since the cross had not been met with any objections in the past it was accepted by most Poles and did not violate their rights. The crucifix was placed in the chamber one night by two conservative politicians in 1997. …

Cuba battling Havana cholera outbreak

HAVANA (Reuters) – Cuban authorities are scrambling to contain a cholera outbreak that has sickened dozens of people in Havana, the capital city of 2.2 million residents and a popular tourism destination. In a brief communiqué issued on Tuesday, the Health Ministry said the outbreak was first detected on January 6, and was being contained. “Fifty-one cases have been confirmed to date,” the statement read, without mentioning fatalities. “Due to the measures adopted transmission is in the phase of extinction,” it said. …

China to offer up to $48,000 reward for food safety informers

BEIJING (Reuters) – China will offer up to 300,000 yuan ($48,200) as a cash reward to people who report on others who violate food safety laws, state media said on Tuesday, as the government tries again to crack down on a persistent problem. “Actions taken to report violations of food and drug safety laws will be rewarded,” state news agency Xinhua said. “The reward for each case, in principle, will not exceed 300,000 yuan.” Rewards will be paid out after the authorities confirm the veracity of the tip-offs, the report said. …

Analysis: Drug industry bets on new blockbusters in 2013

Logo of Swiss pharmaceutical company Roche is pictured in RotkreuzLONDON/NEW YORK (Reuters) – Drugmakers are betting that a new wave of medicines for cancer, diabetes, heart disease, multiple sclerosis and hepatitis will shape up as tomorrow's blockbusters in the coming 12 months. With the industry regaining some of its swagger after winning 39 new drug approvals last year – a record only beaten in 1996 – there are signs the improving trend could continue through 2013. Roche, GlaxoSmithKline, Eli Lilly, Biogen Idec, Gilead Sciences and Novo Nordisk are among those with important new products reaching a critical point in development this year. …

1 929 930 931 932 933 977